
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics Inc. has received FDA approval to lower the age eligibility for its Phase 3 HERO trial of ARD-101 in Prader Willi Syndrome (PWS) from 10 years to 7 years, thereby expanding the potential patient population and enhancing the competitive profile of the drug in the burgeoning PWS treatment landscape. The company is actively pursuing additional avenues to develop treatments for general obesity, positioning itself advantageously against conventional GLP-1 therapies, which, despite strong sales growth, present opportunities for innovative oral alternatives. Although the likelihood of success for ARD-101 has been revised to 50% and its potential launch delayed to 2029, the proactive adjustments in clinical trial criteria and ongoing communication from management indicate a strong commitment to advancing its drug development.
Bears say
Aardvark Therapeutics Inc faces significant uncertainties regarding the clinical trials for its lead candidate, ARD-101, with potential delays of 10 to 11 months in the HERO program timeline, compounded by unpredictable regulatory feedback. The risks outlined, including the possibility of negative clinical results, reliance on partnership developments, and untimely approvals, contribute to a cautious financial outlook. Additionally, concerns over the drug's efficacy and safety, along with potential dilution from financing activities, further exacerbate the negative sentiment towards the company's stock performance.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares